Important It is possible that the main title of the report Facioscapulohumeral Muscular Dystrophy is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.
Muscular Dystrophy, Facioscapulohumeral
Muscular Dystrophy, Landouzy Dejerine
Infantile Facioscapulohumeral Muscular Dystrophy
Facioscapulohumeral muscular dystrophy (FSHD), also known as Landouzy-Dejerine muscular dystrophy, is a neuromuscular disorder. Symptom onset usually occurs in adolescence or early adulthood; however, less commonly, symptoms may become apparent as early as infancy or early childhood.
The disorder is typically initially characterized by weakness of facial, shoulder, and/or upper arm muscles. Associated abnormalities may include an impaired ability to completely close the eyes, limited movements of the lips, and difficulties raising the arms over the head. Affected individuals may also eventually develop weakness and associated wasting (atrophy) of muscles of the hips and thighs and/or involvement of lower leg muscles.
Although the disease course may be variable, FSHD is most typically characterized by relatively slow disease progression. Specific symptoms and findings may also vary in range and severity, including among affected members of the same family (kindred).
FSHD is usually inherited as an autosomal dominant trait. However, in up to approximately 30 percent of affected individuals, there is no apparent family history of the disorder. In some of these cases, FSHD may be due to new genetic changes (mutations) that appear to occur spontaneously for unknown reasons (sporadically).
March of Dimes Birth Defects Foundation 1275 Mamaroneck Avenue White Plains, NY 10605 Tel: (914)997-4488 Fax: (914)997-4763 Tel: (888)663-4637 Email: Askus@marchofdimes.com Internet: http://www.marchofdimes.com
FSH Society, Inc. 450 Bedford Street Lexington, MA 02420 Tel: (781)301-6060 Email: email@example.com Internet: http://www.fshsociety.org
Muscular Dystrophy Association 3300 East Sunrise Drive Tucson, AZ 85718-3208 USA Tel: (520)529-2000 Fax: (520)529-5300 Tel: (800)572-1717 Email: firstname.lastname@example.org Internet: http://www.mda.org/
Muscular Dystrophy Canada 2345 Yonge Street Suite 900 Toronto Ontario, M4P 2E5 Canada Tel: 4164880030 Fax: 4164887523 Tel: 866MUSCLE8 Email: email@example.com Internet: http://www.muscle.ca
Muscular Dystrophy Campaign 61 Southwark Street London, SE1 0HL United Kingdom Tel: 02078034800 Email: firstname.lastname@example.org Internet: http://www.muscular-dystrophy.org
NIH/National Institute of Neurological Disorders and Stroke P.O. Box 5801 Bethesda, MD 20824 Tel: (301)496-5751 Fax: (301)402-2186 Tel: (800)352-9424 TDD: (301)468-5981 Internet: http://www.ninds.nih.gov/
Society for Muscular Dystrophy Information International P.O. Box 7490 Bridgewater Nova Scotia, B4V 2X6 Canada Tel: 9026853961 Fax: 9026853962 Email: email@example.com Internet: http://www.nsnet.org/smdi/
Muscular Dystrophy Association of New Zealand, Inc. PO Box 16-238 Sandringham Auckland, New Zealand Tel: 098150247 Fax: 092777540 Tel: 0800800337 Email: firstname.lastname@example.org Internet: http://www.mda.org.nz/
Muscular Dystrophy Australia 111 Boundary Road North Melbourne VIC 3051 Australia Tel: 61393209555 Fax: 61393209595 Tel: 1800656632 Email: email@example.com Internet: http://www.mda.org.au
European Alliance of Neuromuscular Disorders Associations MDG Malta 4 Gzira Road Gzira, GAR 04 Malta Tel: 0035621346688 Fax: 0035621318024 Email: firstname.lastname@example.org Internet: http://www.eamda.net
Child Neurology Foundation 201 Chicago Ave, #200 Minneapolis, MN 55415 USA Tel: (952)641-6100 Fax: (952)881-6276 Tel: (877)263-5430 Email: email@example.com Internet: http://www.childneurologyfoundation.org
For a Complete Report
This is an abstract of a report from the National Organization for Rare Disorders (NORD). A copy of the complete report can be downloaded free from the NORD website for registered users. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational therapies (if available), and references from medical literature. For a full-text version of this topic, go to www.rarediseases.org and click on Rare Disease Database under "Rare Disease Information".
The information provided in this report is not intended for diagnostic purposes. It is provided for informational purposes only. NORD recommends that affected individuals seek the advice or counsel of their own personal physicians.
It is possible that the title of this topic is not the name you selected. Please check the Synonyms listing to find the alternate name(s) and Disorder Subdivision(s) covered by this report
This disease entry is based upon medical information available through the date at the end of the topic. Since NORD's resources are limited, it is not possible to keep every entry in the Rare Disease Database completely current and accurate. Please check with the agencies listed in the Resources section for the most current information about this disorder.
For additional information and assistance about rare disorders, please contact the National Organization for Rare Disorders at P.O. Box 1968, Danbury, CT 06813-1968; phone (203) 744-0100; web site www.rarediseases.org or email firstname.lastname@example.org
Last Updated: 9/17/2007 Copyright 1992, 1996, 1997, 1998, 1999, 2000, 2002, 2003, 2007 National Organization for Rare Disorders, Inc.
How this information was developed to help you make better health decisions.
Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.